Stage I/Smoldering Myeloma
Addition of Velcade® to Standard Therapy Improves Survival in Multiple Myeloma
(08/29/2008)
In the treatment of multiple myeloma, the addition of Velcade® (bortezomib) to Alkeran® (melphalan) and prednisone significantly improves progression-free and overall survival compared with Alkeran/prednisone only. These results were recently published in the New England Journal of Medicine.
Velcade® Approved for Initial Therapy of Multiple Myeloma
(06/23/2008)
The United States Food and Drug Administration (FDA) has approved Velcade® (bortezomib) as initial therapy for the treatment of multiple myeloma. Velcade is already approved for the treatment of patients with multiple myeloma who have received prior therapies, as well as for patients with mantle cell lymphoma who have received prior therapies. These results were recently published in a press release by Millennium Pharmaceuticals.
Being Overweight Associated with Increased Risk of Several Cancers
(02/19/2008)
Excess bodyweight increases the risk of developing several types of cancer, according to results recently published in The Lancet.
Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma
(01/16/2008)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, additional evidence confirms that the addition of Thalomid® (thalidomide) to Alkeran® (melphalan) and prednisone improves survival in elderly patients with multiple myeloma.
Low-dose Steroids Improve Survival in Multiple Myeloma
(12/14/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, use of low doses of the steroid dexamethasone in combination with Revlimid® (lenalidomide) provided significantly improved survival in multiple myeloma compared with higher-doses of the steroid in this treatment combination.
More...
Stages II-III
Addition of Velcade® to Standard Therapy Improves Survival in Multiple Myeloma
(08/29/2008)
In the treatment of multiple myeloma, the addition of Velcade® (bortezomib) to Alkeran® (melphalan) and prednisone significantly improves progression-free and overall survival compared with Alkeran/prednisone only. These results were recently published in the New England Journal of Medicine.
Velcade® Approved for Initial Therapy of Multiple Myeloma
(06/23/2008)
The United States Food and Drug Administration (FDA) has approved Velcade® (bortezomib) as initial therapy for the treatment of multiple myeloma. Velcade is already approved for the treatment of patients with multiple myeloma who have received prior therapies, as well as for patients with mantle cell lymphoma who have received prior therapies. These results were recently published in a press release by Millennium Pharmaceuticals.
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant
(04/18/2008)
A recently published study indicates that the type of initial chemotherapy for multiple myeloma has no impact on the outcome of patients who later undergo autologous stem cell transplant. These findings appeared in an early online publication of Bone Marrow Transplantation.
Additional Evidence Shows Thalomid® Improves Survival in Elderly with Multiple Myeloma
(01/16/2008)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, additional evidence confirms that the addition of Thalomid® (thalidomide) to Alkeran® (melphalan) and prednisone improves survival in elderly patients with multiple myeloma.
Low-dose Steroids Improve Survival in Multiple Myeloma
(12/14/2007)
According to results recently presented at the 2007 annual meeting of the American Society of Hematology, use of low doses of the steroid dexamethasone in combination with Revlimid® (lenalidomide) provided significantly improved survival in multiple myeloma compared with higher-doses of the steroid in this treatment combination.
More...
Recurrent
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates
(08/20/2008)
Patients who undergo preventive dental care prior to receiving therapy with bisphosphonates have a significantly reduced risk of developing osteonecrosis of the jaw. These results were published in an early online publication in the Annals of Oncology.
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant
(04/18/2008)
A recently published study indicates that the type of initial chemotherapy for multiple myeloma has no impact on the outcome of patients who later undergo autologous stem cell transplant. These findings appeared in an early online publication of Bone Marrow Transplantation.
Revlimid® Improves Survival in Relapsed Multiple Myeloma
(11/26/2007)
According to two articles recently published in the New England Journal of Medicine, Revlimid® (lenalidomide) improves survival for patients with multiple myeloma that has returned following prior therapies.
Velcade® as New Standard of Care for Initial Therapy in Multiple Myeloma
(09/18/2007)
According to results recently published by Millennium Pharmaceuticals, the addition of Velcade® (bortezomib) to the chemotherapy agent Alkeran® (melphalan) and the steroid prednisone significantly improves survival over Alkeran/prednisone only as initial therapy for multiple myeloma.
Velcade® plus Doxil® Approved for Multiple Myeloma
(05/23/2007)
The United States Food and Drug Administration (FDA) recently approved the treatment combination consisting of Velcade® (bortezomib) plus Doxil® (doxorubicin HCl liposome injection) for the treatment of multiple myeloma in patients who have received at least one prior treatment but have not been previously treated with Velcade.
More...